Tuberculosis treatment trial for new patients
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have active tuberculosis confirmed by symptoms, imaging, and a lab test.
- You have not received any tuberculosis treatment before.
- You are willing to have HIV testing and provide samples for research.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a shorter-course treatment for tuberculosis (TB) in people 65 and older. It compares a new ultra-short regimen to the usual longer one, using the drugs bedaquiline, linezolid, and pyrazinamide, to see if a shorter treatment is just as effective and safer for older adults.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.